JOP20170131B1 - مركبات 1-تيترا هيدروبيرانييل كاربونيل -2،3-ديهيدرو -1 h- اندول لعلاج السرطان - Google Patents
مركبات 1-تيترا هيدروبيرانييل كاربونيل -2،3-ديهيدرو -1 h- اندول لعلاج السرطانInfo
- Publication number
- JOP20170131B1 JOP20170131B1 JOP/2017/0131A JOP20170131A JOP20170131B1 JO P20170131 B1 JOP20170131 B1 JO P20170131B1 JO P20170131 A JOP20170131 A JO P20170131A JO P20170131 B1 JOP20170131 B1 JO P20170131B1
- Authority
- JO
- Jordan
- Prior art keywords
- cancer
- compounds
- dihydro
- tetrahydropyranylcarbonyl
- indole compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
يتعلق الاختراع الحالي بمركبات 2، 3-داي هيدرو-1H- إندول جديدة معينة، تركيبات صيدلية تشتمل على المركبات، وطرق استخدام المركبات لعلاج السرطان، وبصورة أكثر تحديدًا لعلاج السرطان تم اختيارها من المجموعة المتكونة من الورم الميلانيني، اللوكيميا النخاعية الحادة، لوكيميا الخلايا اللمفية المزمنة، سرطان القولون والمستقيم، سرطان الثدي، سرطان الرئة، سرطان المبيض، كارسينوما قناة فالوب، الكارسينوما البريتونية الرئيسية، السرطان العنقي، السرطان المعدي، سرطان الكبد، سرطان البنكرياس، سرطان الغدة الدرقية، الورم النخاعي، الورم اللمفاوي غير هودكينز، والورم اللمفاوي هودكينز.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662348457P | 2016-06-10 | 2016-06-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20170131B1 true JOP20170131B1 (ar) | 2021-08-17 |
Family
ID=59031409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2017/0131A JOP20170131B1 (ar) | 2016-06-10 | 2017-05-24 | مركبات 1-تيترا هيدروبيرانييل كاربونيل -2،3-ديهيدرو -1 h- اندول لعلاج السرطان |
Country Status (40)
| Country | Link |
|---|---|
| US (2) | US10759786B2 (ar) |
| EP (1) | EP3468965B1 (ar) |
| JP (1) | JP6632746B2 (ar) |
| KR (1) | KR102241258B1 (ar) |
| CN (1) | CN109641881B (ar) |
| AR (1) | AR108586A1 (ar) |
| AU (1) | AU2017277833B2 (ar) |
| BR (1) | BR112018072872A2 (ar) |
| CA (1) | CA3027035C (ar) |
| CL (1) | CL2018003543A1 (ar) |
| CO (1) | CO2018013251A2 (ar) |
| CR (1) | CR20180579A (ar) |
| CY (1) | CY1123660T1 (ar) |
| DK (1) | DK3468965T3 (ar) |
| DO (1) | DOP2018000278A (ar) |
| EA (1) | EA037419B1 (ar) |
| EC (1) | ECSP19001734A (ar) |
| ES (1) | ES2797981T3 (ar) |
| HR (1) | HRP20200769T1 (ar) |
| HU (1) | HUE050155T2 (ar) |
| IL (1) | IL263497B (ar) |
| JO (1) | JOP20170131B1 (ar) |
| LT (1) | LT3468965T (ar) |
| MA (1) | MA45224B1 (ar) |
| MD (1) | MD3468965T2 (ar) |
| ME (1) | ME03744B (ar) |
| MX (1) | MX382877B (ar) |
| MY (1) | MY197462A (ar) |
| NZ (1) | NZ748500A (ar) |
| PE (1) | PE20190378A1 (ar) |
| PH (1) | PH12018502572A1 (ar) |
| PL (1) | PL3468965T3 (ar) |
| PT (1) | PT3468965T (ar) |
| RS (1) | RS60322B1 (ar) |
| SG (1) | SG11201809625RA (ar) |
| SI (1) | SI3468965T1 (ar) |
| TW (1) | TWI671294B (ar) |
| UA (1) | UA122526C2 (ar) |
| WO (1) | WO2017213919A1 (ar) |
| ZA (1) | ZA201807688B (ar) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10738035B2 (en) | 2015-05-13 | 2020-08-11 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| CN109069488B (zh) | 2016-03-07 | 2021-09-07 | 英安塔制药有限公司 | 乙型肝炎抗病毒剂 |
| EP3675637A4 (en) | 2017-08-28 | 2021-05-19 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| WO2019089412A1 (en) * | 2017-11-01 | 2019-05-09 | Merck Sharp & Dohme Corp. | Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
| US20210002371A1 (en) * | 2017-12-21 | 2021-01-07 | Brian A. Sherer | Combination of an anti-pd-l1 antibody and ido1 inhibitor for the treatment of cancer |
| WO2019143902A2 (en) | 2018-01-22 | 2019-07-25 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| EP3836928B1 (en) * | 2018-08-17 | 2024-02-14 | Merck Sharp & Dohme LLC | Novel substituted tetrahydroquinoline compounds as indoleamine 2,3-dioxygenase inhibitors |
| MX2021003253A (es) | 2018-09-21 | 2021-08-11 | Enanta Pharm Inc | Heterociclos funcionalizados como agentes antivirales. |
| US12065438B2 (en) * | 2018-11-06 | 2024-08-20 | Merck Sharp & Dohme Llc | Substituted tricyclic compounds as indoleamine 2,3-dioxygenase inhibitors |
| SG11202105007TA (en) | 2018-11-21 | 2021-06-29 | Enanta Pharm Inc | Functionalized heterocycles as antiviral agents |
| US11236111B2 (en) | 2019-06-03 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| WO2020247575A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| US11760755B2 (en) | 2019-06-04 | 2023-09-19 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| WO2021007488A1 (en) | 2019-07-11 | 2021-01-14 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| US11236108B2 (en) | 2019-09-17 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| WO2021188414A1 (en) | 2020-03-16 | 2021-09-23 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| CN114105961B (zh) * | 2021-12-10 | 2023-09-12 | 海南梵圣生物科技有限公司 | 一种ido1抑制剂(ly-3381916)制备方法 |
| CN114213310B (zh) * | 2021-12-31 | 2024-02-23 | 中国药科大学 | 吲哚啉化合物及其衍生物、制备方法、药物组合物和应用 |
| AU2024354068A1 (en) * | 2023-09-25 | 2026-01-29 | Biohybrid Solutions Holdings, Inc. | Methods for and compositions of non-peg bioconjugates with ultra-high drug-to-agent ratio |
| WO2025140363A1 (zh) * | 2023-12-27 | 2025-07-03 | 海思科医药集团股份有限公司 | 一种苯基哌啶衍生物的制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004089896A1 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS |
| BR122020016659B8 (pt) * | 2005-05-10 | 2021-07-27 | Incyte Holdings Corp | moduladores de 2,3-dioxigenase de indolamina e métodos de modulação de atividade de inibição e de imunossupressão |
| US7622495B2 (en) * | 2006-10-03 | 2009-11-24 | Neurim Pharmaceuticals (1991) Ltd. | Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents |
| BRPI0907492A2 (pt) | 2008-02-07 | 2017-06-13 | Abbott Lab | derivados amida como moduladores alostéricos positivos e métodos de sua utilização |
| BR122019015876B8 (pt) * | 2008-07-08 | 2021-07-27 | Incyte Holdings Corp | compostos derivados de 1,2,5-oxadiazóis, composição, bem como seus usos |
| NO2694640T3 (ar) * | 2011-04-15 | 2018-03-17 | ||
| JP6313415B2 (ja) * | 2013-03-15 | 2018-04-18 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｉｄｏ阻害剤 |
| RS60878B1 (sr) * | 2014-04-04 | 2020-11-30 | Iomet Pharma Ltd | Derivati indola za upotrebu u medicini |
| AR102537A1 (es) * | 2014-11-05 | 2017-03-08 | Flexus Biosciences Inc | Agentes inmunomoduladores |
| WO2017112954A1 (en) * | 2015-12-23 | 2017-06-29 | Moonshot Pharma Llc | Methods for inducing an immune response by promoting premature termination codon read-through |
-
2017
- 2017-05-24 JO JOP/2017/0131A patent/JOP20170131B1/ar active
- 2017-05-24 AR ARP170101413A patent/AR108586A1/es not_active Application Discontinuation
- 2017-05-25 TW TW106117300A patent/TWI671294B/zh not_active IP Right Cessation
- 2017-05-31 PL PL17728990T patent/PL3468965T3/pl unknown
- 2017-05-31 PE PE2018003199A patent/PE20190378A1/es unknown
- 2017-05-31 RS RS20200623A patent/RS60322B1/sr unknown
- 2017-05-31 KR KR1020187035215A patent/KR102241258B1/ko not_active Expired - Fee Related
- 2017-05-31 ME MEP-2020-98A patent/ME03744B/me unknown
- 2017-05-31 CN CN201780035976.4A patent/CN109641881B/zh not_active Expired - Fee Related
- 2017-05-31 JP JP2018563823A patent/JP6632746B2/ja not_active Expired - Fee Related
- 2017-05-31 WO PCT/US2017/035097 patent/WO2017213919A1/en not_active Ceased
- 2017-05-31 HU HUE17728990A patent/HUE050155T2/hu unknown
- 2017-05-31 BR BR112018072872-1A patent/BR112018072872A2/pt not_active Application Discontinuation
- 2017-05-31 EP EP17728990.7A patent/EP3468965B1/en active Active
- 2017-05-31 MA MA45224A patent/MA45224B1/fr unknown
- 2017-05-31 PT PT177289907T patent/PT3468965T/pt unknown
- 2017-05-31 ES ES17728990T patent/ES2797981T3/es active Active
- 2017-05-31 MX MX2018015275A patent/MX382877B/es unknown
- 2017-05-31 SI SI201730252T patent/SI3468965T1/sl unknown
- 2017-05-31 EA EA201892479A patent/EA037419B1/ru unknown
- 2017-05-31 US US16/307,612 patent/US10759786B2/en active Active
- 2017-05-31 MY MYPI2018002369A patent/MY197462A/en unknown
- 2017-05-31 NZ NZ748500A patent/NZ748500A/en not_active IP Right Cessation
- 2017-05-31 HR HRP20200769TT patent/HRP20200769T1/hr unknown
- 2017-05-31 AU AU2017277833A patent/AU2017277833B2/en not_active Ceased
- 2017-05-31 LT LTEP17728990.7T patent/LT3468965T/lt unknown
- 2017-05-31 UA UAA201811735A patent/UA122526C2/uk unknown
- 2017-05-31 CA CA3027035A patent/CA3027035C/en active Active
- 2017-05-31 MD MDE20190462T patent/MD3468965T2/ro not_active IP Right Cessation
- 2017-05-31 SG SG11201809625RA patent/SG11201809625RA/en unknown
- 2017-05-31 US US15/609,115 patent/US9872853B2/en active Active
- 2017-05-31 CR CR20180579A patent/CR20180579A/es unknown
- 2017-05-31 DK DK17728990.7T patent/DK3468965T3/da active
-
2018
- 2018-11-15 ZA ZA2018/07688A patent/ZA201807688B/en unknown
- 2018-12-04 IL IL263497A patent/IL263497B/en active IP Right Grant
- 2018-12-06 CO CONC2018/0013251A patent/CO2018013251A2/es unknown
- 2018-12-06 PH PH12018502572A patent/PH12018502572A1/en unknown
- 2018-12-10 CL CL2018003543A patent/CL2018003543A1/es unknown
- 2018-12-10 DO DO2018000278A patent/DOP2018000278A/es unknown
-
2019
- 2019-01-09 EC ECSENADI20191734A patent/ECSP19001734A/es unknown
-
2020
- 2020-06-05 CY CY20201100508T patent/CY1123660T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20170131B1 (ar) | مركبات 1-تيترا هيدروبيرانييل كاربونيل -2،3-ديهيدرو -1 h- اندول لعلاج السرطان | |
| ZA201906832B (en) | Novel psma-binding agents and uses thereof | |
| MX2021003478A (es) | Compuestos utiles como inhibidores de cinasa. | |
| EA201891200A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| MX2019001471A (es) | Anticuerpos anti-siglec-7 para el tratamiento del cancer. | |
| EA201791208A1 (ru) | Антитела к cd38 для лечения острого миелолейкоза | |
| EA201692513A1 (ru) | Ингибиторы лизин-специфической деметилазы-1 | |
| EA201790376A1 (ru) | Ингибиторы лизин-специфической деметилазы-1 | |
| EA201891344A1 (ru) | Новые агонисты рецептора апелина и способы применения | |
| EA201792169A1 (ru) | 5'-замещенные нуклеозидные соединения | |
| EA201790082A1 (ru) | Ингибиторы лизин-специфической демитилазы-1 | |
| EP3925969C0 (en) | Peptide compounds and peptide conjugates for the treatment of cancer by receptor-mediated chemotherapy | |
| EA201790502A1 (ru) | Ингибиторы гистоновых диметилаз | |
| BR112016017781A2 (pt) | Compostos de pirazolona e usos dos mesmos | |
| EA201792287A1 (ru) | Способы лечения рака | |
| MX393992B (es) | Compuestos de aminotiazol como inhibidores de la proteina quinasa | |
| EA201992315A1 (ru) | Композиции и способы для лечения рака легкого | |
| EP3566705A4 (en) | COMPOSITION FOR THE PREVENTION OR TREATMENT OF METASTATIC OVARIAN CANCER, ENDOMETRIC CANCER OR BREAST CANCER | |
| EA201792288A1 (ru) | Способы лечения рака | |
| EA201691896A1 (ru) | Соединения и способы их применения | |
| EA201790604A1 (ru) | Ингибиторы гистондеметилазы | |
| AU2017242908A1 (en) | Ferric maltol compositions for use in the treatment or prevention of cancer and tumours | |
| EA201792380A1 (ru) | Новые ингибиторы epha4, нацеленные на его лиганд-связывающий домен | |
| PH12020551193A1 (en) | Certain chemical entities, compositions, and methods | |
| EA201691846A1 (ru) | Композиции и способы лечения рака печени |